(Q45745369)

15 December 2017

title

Long-term results of famciclovir for recurrent or de novo hepatitis B virus infection after liver transplantation (English)

1 reference

15 December 2017

main subject

liver transplantation

1 reference

1 reference

5

1 reference

15 December 2017

author name string

N Rayes

1

1 reference

15 December 2017

D Seehofer

2

1 reference

15 December 2017

W O Bechstein

3

1 reference

15 December 2017

A R Müller

4

1 reference

15 December 2017

R Neuhaus

6

1 reference

15 December 2017

P Neuhaus

7

1 reference

15 December 2017

publication date

1 December 1999

1 reference

15 December 2017

published in

Clinical Transplantation

1 reference

15 December 2017

volume

13

1 reference

15 December 2017

issue

6

1 reference

15 December 2017

page(s)

447-452

1 reference

15 December 2017

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Natural course of de novo hepatitis B virus infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Famciclovir therapy for recurrent hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Hepatitis B virus infection and liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Survival after liver transplantation for chronic hepatitis B using reduced immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

Retransplantation in hepatitis B--a multicenter experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Liver transplantation in European patients with the hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Should hepatitis B immunoglobulin therapy be discontinued after HBV reinfection following liver transplantation?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Follow-up of recurrent hepatitis B and delta infection in liver allograft recipients after treatment with recombinant interferon-alpha

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Combination therapy for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Lamivudine resistance inimmunocompetent chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Interferon alfa for recurrent hepatitis B infection after liver transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-0012.1999.130602.X

7 January 2021

10.1034/J.1399-0012.1999.130602.X

Identifiers

DOI

1 reference

15 December 2017

1 reference

15 December 2017